ribosomal protein S29Genealiases: DBA13 · S29 · uS14
Q-omics provides the consensus-scored RPS29 profile across patient tissues and cancer cell-line models. RPS29 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS29 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, RPS29 protein abundance shows 22,175 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight ACC, LIHC, and CCRCC as cancer lineages where RPS29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS29 survival associations across molecular data types. RPS29 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS29 RNA expression–survival associations across cancer types. High RPS29 expression shows unfavorable associations in ACC, KIRP and HNSC, but favorable associations in UVM, LGG and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS29 RNA expression.
This table summarizes RPS29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RPS29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS29 shows lower tumor expression in BRCA and KICH and higher tumor expression in LIHC, CHOL, KIRC and KIRP. The LIHC box plot shows higher RPS29 RNA expression in tumor versus normal tissue (log2 FC = +0.682, t-test p < 0.001).
This table shows molecular features associated with RPS29 in patient tissues and cancer cell lines. In patient samples, RPS29 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS29 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and PANCREAS.
